Certara (CERT) Initiation of Coverage
Investment Summary
- Certara, Inc. has delivered consistent revenue growth and strong adjusted EBITDA margins over the last three years, driven by its leadership in biosimulation software and technology-enabled services for model-informed drug development (MIDD).
- The company has aggressively expanded its platform through acquisitions (Chemaxon, Formedix, Applied BioMath), AI integration, and cloud transition, with software now the fastest-growing part of the business (43.8% of FY2025 revenue, up from 37% in FY2023).
- Certara divested its regulatory and medical writing business in May 2026, sharpening focus on core technology and improving revenue predictability.
- Despite robust bookings and high net retention rates, Certara has reported persistent GAAP net losses, though these have narrowed significantly.
- Key risks include execution challenges from organizational restructuring, margin compression post-divestiture, customer concentration, and exposure to biopharma R&D cycles.
Business Overview
Certara is a global leader in biosimulation science, technology, and consulting services for drug discovery and development. Its offerings span software products (Simcyp, Phoenix, Pinnacle 21, Chemaxon, Certara Cloud, CertaraIQ) and technology-enabled services (consulting, QSP, regulatory writing, divested in 2026). The company serves over 2,600 life sciences companies, academic institutions, and 20+ global drug regulatory agencies.
Segment Revenue Mix (FY2025)
| Segment | Revenue ($M) | % of Total Revenue |
|---|---|---|
| Software | 183.3 | 43.8% |
| Services | 235.6 | 56.2% |
| Total | 418.8 | 100% |
Financial Snapshot: Last 3 Fiscal Years
| Fiscal Year | Revenue ($M) | YoY Growth | Net Income (Loss) ($M) | Adjusted EBITDA ($M) | Operating Cash Flow ($M) | Cash & Equiv. ($M) | Term Loan Debt ($M) | Share Repurchases ($M) |
|---|---|---|---|---|---|---|---|---|
| 2025 | 418.8 | +9.0% | -1.6 | 134.5 | 96.3 | 189.4 | 295.5 | 42.6 |
| 2024 | 385.1 | +8.7% | -12.1 | 122.0 | 80.5 | 179.2 | 298.5 | - |
| 2023 | 354.3 | +7.6% | -55.4 | 123.1 | 82.8 | 235.0 | 294.5 | - |
Segment Analysis: Software and Services (FY2023-FY2025)
| Fiscal Year | Software Revenue ($M) | Software YoY Growth | Services Revenue ($M) | Services YoY Growth |
|---|---|---|---|---|
| 2025 | 183.3 | +18% | 235.6 | +3% |
| 2024 | 155.7 | +18% | 229.5 | +3% |
| 2023 | 131.7 | +14% | 222.7 | +1% |
Quarterly Actuals: Most Recent Periods (Q3 2025-Q2 2026)
| Quarter | Revenue ($M) | YoY Growth | Software Revenue ($M) | Software YoY Growth | Services Revenue ($M) | Services YoY Growth | Adj. EBITDA ($M) | Adj. EBITDA Margin (%) | Net Income ($M) | Adj. Diluted EPS ($) | Cash & Equiv. ($M) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 93.3 | +1% | 48.8 | +4% | 44.5 | -3% | 26.2 | 28.1 | -6.1 | 0.08 | 184.1 |
| Q1 2026 | 106.9 | +1% | 49.7 | +7% | 57.2 | -4% | 31.7 | 30 | -8.8 | 0.09 | 149.5 |
| Q4 2025 | 103.6 | +3% | 46.4 | +10% | 57.3 | -1% | 32.5 | 31 | -5.9 | 0.09 | 189.4 |
| Q3 2025 | 104.6 | +10% | 43.8 | +22% | 60.8 | +3% | 35.2 | 34 | 1.5 | 0.14 | 172.7 |
Bookings and Retention Metrics (FY2023-FY2025)
| Fiscal Year | Bookings ($M) | Net Retention Rate (%) |
|---|---|---|
| 2025 | 482.1 | 105.3 |
| 2024 | 445.3 | 108.8 |
| 2023 | 402.3 | 108.4 |
Bullish and Bearish Points
| Bullish Points | Bearish Points |
|---|---|
| Consistent revenue growth and strong adjusted EBITDA margin | Persistent GAAP net losses, though narrowing |
| High net retention rates (105-109%) and robust bookings | High customer concentration: top 10 customers = 24% of FY2025 revenue |
| Strategic acquisitions expanding product portfolio and market reach | Exposure to biopharma R&D spending cycles and regulatory changes |
| Strong cash position and liquidity, with positive operating cash flow | Integration risks from multiple acquisitions |
| Market leadership in biosimulation and regulatory science | Competition from larger tech firms and open-source solutions |
| Diversified customer base (no single customer >10% of revenue) | Potential pricing pressure from large customers and procurement departments |
| Software share of revenue up to 43.8% in FY2025 from 37% in FY2023 | Services revenue declined in Q2 2026 (-3% YoY); services bookings down 6% YoY in Q2 2026 |
| AI integration accelerating: 85% of new code AI-assisted, 65% increase in dev productivity | Adjusted EBITDA margin declined to 28.1% in Q2 2026 (from 30-32% prior guidance) due to stranded costs |
| Divestiture of regulatory/medical writing business improves focus and predictability | Execution challenges and go-to-market realignment still ongoing; services pipeline conversion risk |
| Partnerships with NVIDIA and Altasciences to drive innovation and new use cases | Net income negative in Q1 and Q2 2026; adjusted EPS compressed |
| Pipeline up 27% YoY in Q2 2026; strong ARR accumulation in software | Macro headwinds and pharma/biotech consolidation could slow deal cycles |
| Realization of $13M run-rate cost savings and improved operating leverage post-divestiture | Stranded costs from divestiture impacting margins; cost savings yet to be fully realized |
Positive and Negative Catalysts
| Positive Catalysts | Negative Catalysts |
|---|---|
| Further adoption of biosimulation and MIDD by regulators and industry | Reduction in biopharma R&D budgets or government funding |
| Successful integration and cross-sell from recent acquisitions | Regulatory changes reducing demand for modeling/simulation services |
| Expansion into new geographies and customer segments | Delays or defects in new software releases |
| Increased AI/ML adoption in drug development workflows | Adverse macroeconomic conditions impacting customer budgets |
| New product launches (e.g., Certara.AI, next-gen CoAuthor) | Loss of major customers or failure to renew key contracts |
| Successful execution of new go-to-market model and commercial leadership | Failure to convert expanded pipeline into bookings/revenue, especially in services |
| Acceleration of AI-enabled platform and product launches (NVIDIA partnership, next-gen platform) | Further margin compression if cost savings lag or stranded costs persist |
| Continued shift to cloud-based software (Phoenix Cloud, Simcyp) and higher ARR visibility | Prolonged softness in Tier 1 pharma spending or macro-driven delays in clinical trial starts |
| International expansion (first major Simcyp win in China, growth in Middle East/Japan) | Competition from internal pharma AI initiatives |
| Regulatory tailwinds (ICH M15, FDA/EMA guidance on MIDD and QSP) | Regulatory uncertainty or slower-than-expected adoption of new modeling approaches |
Top Questions to Ask Before Investing
- Path to Sustainable Profitability: What are the key levers to move from adjusted EBITDA profitability to consistent GAAP net income?
- Acquisition Integration: How is Certara managing integration risk and realizing synergies from recent acquisitions (Chemaxon, Formedix, ABM)?
- Customer Concentration: How does Certara mitigate risks associated with high revenue concentration among its top 10 customers?
- Competitive Threats: How does Certara plan to defend its market share against larger technology companies and open-source alternatives?
- Regulatory Environment: What impact could changes in global regulatory frameworks have on Certara’s business model and growth prospects?
- AI and Technology Investment: How is Certara leveraging AI/ML to differentiate its offerings, and what is the expected ROI on these investments?
- R&D Spending Sensitivity: How exposed is Certara to fluctuations in biopharma R&D budgets, and what strategies are in place to diversify revenue streams?
- Capital Allocation: What is the company’s approach to capital allocation between M&A, R&D, share repurchases, and debt reduction?
- Margin Trajectory: When will the company fully realize the $13M in cost savings and return to/expand EBITDA margins post-divestiture?
- International Growth: What is the strategy and expected contribution from international markets (e.g., China, Japan, Middle East) over the next 2-3 years?
- Product Innovation: What are the key milestones for new product launches (e.g., CertaraIQ, Phoenix Cloud, D360/Chemaxon integration), and how are customers responding?
- Management Stability: With recent C-suite changes, how stable is the leadership team, and what is the risk of further turnover during this transition period?
